psychopharmacology. With three professors and a senior lecturer in pharmacology and two eminent clinicians as speakers, the programme attracted a sizeable audience whose expectations were not disappointed.
Dr Anthony Thorley (Newcastle) set the tone with an informative review of drug abuse and dependence in the UK past and present and some speculation about future trends. He predicted that tobacco and alcohol consumption will decline but the abuse of prescribed, bought or illegal drugs will increase. He discussed dependence in terms of physiology, psychology, habit and culture and provided some credible answers to the often baffling question, 'Why do people take drugs?' Dr Heather Ashton (Newcastle) reviewed recent observations of the effects of one particular drug of abuse, namely cannabis, and concluded that its adverse effects outweigh any possible therapeutic effects. She presented data demonstrating that both the subjective and electrophysiological effects of cannabis are dependent on the user's personality structure, and marshalled evidence to support the view that cannabis exerts its principal effect on the limbic system of the brain.
Professor Malcolm Lader (Institute of Psychiatry), in a stimulating paper entitled 'Benzodiazepines: panacea or poison?', defined the features of the benzodiazepine withdrawal syndrome as increased anxiety, heightened perception and, in a few cases, delirium, fits and psychosis. He reckoned that as many as one-third of patients receiving benzodiazepines for over 4 months develop some symptoms on drug withdrawal.
Benzodiazepines, although effective anxiolytic drugs, should be used with discrimination for the shortest-possible time.
'Report of meeting of Section of Psychiatry, 5 December 1980 Professor Own Wade (Birmingham) presented some interesting data on the prescribing of hypnotics collected by an international association of clinical pharmacologists, the drug Utilization Research Group (DURG), who have access to prescribing information from several European countries. Using the concept of the 'daily drug dose', Professor Wade demonstrated variations in the prescribing of hypnotics between the Scandinavian countries, Finland, Czechoslovakia and Northern Ireland and traced the decline in the popularity of barbiturates and the corresponding rise in the prescription of tranquillizers and nonbarbiturate hypnotics during the past decade.
Professor Michael Rawlins (Newcastle) identified the factors influencing the efficacy of tricyclic antidepressants as diagnosis, heterogeneity of disease, patient compliance, pharmacokinetics and pharmacodynamics. Reviewing the evidence for the 'therapeutic window', he concluded that this has been confirmed for nortriptyline, that it partially exists for amitriptyline, but is 'not proven' for other antidepressants.
Dr Peter Tyrer (Nottingham) ended the day with a review of the pros and cons of the monoamine oxidase (MAO) inhibitor drugs, with particular reference to phenelzine, and concluded that they are of particular value in depressive syndromes with accompanying hypochondriasis, somatic anxiety, agoraphobia, social phobias, irritability and anergia. He concluded that MAO inhibitor drugs deserve at least a stay of execution.
The high standard of the speakers, cogent contributions from the floor, the genial chairmanship of the President, Dr Kurt Schapira, exellent catering and the efficient but inobtrusive organization of the. Department of Postgraduate Medical Education, Wyeth Laboratories, combined to create an absorbing, enjoyable and educative experience. One felt that the steely-eyed scientists of past generations whose portraits adorned the walls would have approved. 
